Cargando…
A novel oral formulation of the melanocortin-1 receptor agonist PL8177 resolves inflammation in preclinical studies of inflammatory bowel disease and is gut restricted in rats, dogs, and humans
INTRODUCTION: PL8177 is a potent and selective agonist of the melanocortin 1 receptor (MC1R). PL8177 has shown efficacy in reversing intestinal inflammation in a cannulated rat ulcerative colitis model. To facilitate oral delivery, a novel, polymer-encapsulated formulation of PL8177 was developed. T...
Autores principales: | Dodd, John, Jordan, Robert, Makhlina, Marie, Barnett, Keith, Roffel, Ad, Spana, Carl, Obr, Alison, Dhingra, Priyanka, Kayne, Paul S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9986545/ https://www.ncbi.nlm.nih.gov/pubmed/36891301 http://dx.doi.org/10.3389/fimmu.2023.1083333 |
Ejemplares similares
-
Pharmacokinetics of the Melanocortin Type 1 Receptor Agonist PL8177 After Subcutaneous Administration
por: Dodd, John, et al.
Publicado: (2021) -
Pro-resolving and anti-arthritic properties of the MC(1) selective agonist PL8177
por: Garrido-Mesa, Jose, et al.
Publicado: (2022) -
Probing the Role of Melanocortin Type 1 Receptor Agonists in Diverse Immunological Diseases
por: Spana, Carl, et al.
Publicado: (2019) -
Efficacy and Safety of the Melanocortin Pan-Agonist PL9643 in a Phase 2 Study of Patients with Dry Eye Disease
por: Evans, David, et al.
Publicado: (2023) -
Melanocortin therapies to resolve fibroblast-mediated diseases
por: Khodeneva, Natalya, et al.
Publicado: (2023)